Neuro-oncology advances
Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect.
Neuro-oncology advances
Level I and II deficits-A clinical survey on international practice of awake craniotomy and definitions of postoperative "major" and "minor" deficits.
Neuro-oncology advances
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival.
Neuro-oncology advances
Estimating overall survival of glioblastoma patients using clinical variables, tumor size, and location.
Neuro-oncology advances
An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.
Neuro-oncology advances
Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop.
Neuro-oncology advances
Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma.
Neuro-oncology advances